<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9156">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704205</url>
  </required_header>
  <id_info>
    <org_study_id>NL81882.018.22</org_study_id>
    <nct_id>NCT05704205</nct_id>
  </id_info>
  <brief_title>The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)</brief_title>
  <acronym>UPDATE</acronym>
  <official_title>The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema): A Multicenter Randomized Controlled Trial of Narrowband UVB Versus Optimized Topical Therapy in Patients With Atopic Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized controlled trial is to study the (cost)effectiveness of NB-UVB&#xD;
      phototherapy in patients with atopic eczema/atopic dermatitis.&#xD;
&#xD;
      Half of the participants will undergo a course of NB-UVB phototherapy of 8-16 weeks and apply&#xD;
      optimal topical therapy (OTT) for a minimum of 3 months. Researchers will compare the&#xD;
      outcomes of this group with the other half of participants that apply OTT only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atopic eczema (AE) is a chronic fluctuating dermatological disease characterized by a&#xD;
      pruritic inflammation of the skin. The condition poses a high global (financial) burden. One&#xD;
      of the therapeutic options of AE is phototherapy, with narrowband UVB (NB-UVB) being the most&#xD;
      common. The evidence of the (cost-)effectiveness of NB-UVB, however, is scarce and of low&#xD;
      quality.&#xD;
&#xD;
      The objective of this pragmatic multicenter single blinded randomized controlled trial is&#xD;
      comparing the effectiveness and cost-effectiveness of narrowband ultraviolet B with optimal&#xD;
      topical therapy (NB-UVB+OTT) versus OTT at 3 months in adult patients with insufficient&#xD;
      control of their AE with standard topical treatment, for whom dermatologist and patient&#xD;
      jointly believe that NB-UVB or OTT is needed.&#xD;
&#xD;
      Participants that are randomized into the NB-UVB+OTT group will receive an NB-UVB course (at&#xD;
      home or at the outpatient clinic) for at least 8 and up to 16 weeks, combined with OTT for at&#xD;
      least 3 months. Participants in the control group (OTT group) will apply OTT for at least 3&#xD;
      months. Visits will occur at baseline and 1-3-6-9-12 months after start. At baseline, patient&#xD;
      information is collected including an evaluation of medical history and a physical&#xD;
      examination to assess Fitzpatrick skin type and physician-reported clinical signs. During&#xD;
      each visit patients are asked to fill out questionnaires. Risks are expected to be as in&#xD;
      daily practice.&#xD;
&#xD;
      Primary study parameters/outcome of the study is the percentage of patients with EASI50 (a&#xD;
      decrease of the Eczema Area and Severity Index of 50%) at 3 month follow-up. Secondary study&#xD;
      parameters/outcome of the study include delta EASI, physician-reported clinical signs,&#xD;
      patient-reported symptoms, quality of life, long-term control, cost-effectiveness, side&#xD;
      effects at 1-3-6-9-12 months, quantity and potency topical steroid usage, time to starting&#xD;
      systemic therapy, patient satisfaction with received treatment, percentage of patients&#xD;
      reaching Treatment Target goals and percentage of drop-outs with reasons at 3-6-9-12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients that reach EASI50</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of patients that reach a 50% reduction of the EASI (Eczema Area and Severity Index) at 3 month follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta EASI</measure>
    <time_frame>3 months</time_frame>
    <description>Change in EASI (Eczema Area and Severity Index) at 3 month follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>1 year</time_frame>
    <description>Questionnaire-based calculation of medical consumption- and productivity costs in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>Questionnaire-based review of quality of life, patient satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to start systemic therapy</measure>
    <time_frame>1 year</time_frame>
    <description>The time to start of systemic AE treatment in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of topical steroid usage</measure>
    <time_frame>1 year</time_frame>
    <description>The amount of used topical corticosteroids in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potency of topical steroid usage</measure>
    <time_frame>1 year</time_frame>
    <description>The potency (I-IV) of used topical corticosteroids in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Atopic Dermatitis Eczema</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>NB-UVB+OTT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-16 weeks of NB-UVB phototherapy combined with (a minimum of) 3 months of optimal topical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal topical therapy (OTT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(a minimum of) 3 months of optimal topical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NB-UVB phototherapy</intervention_name>
    <description>Narrowband ultraviolet B irradiation 3 times a week</description>
    <arm_group_label>NB-UVB+OTT</arm_group_label>
    <other_name>Narrowband ultraviolet B phototherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Optimal topical therapy</intervention_name>
    <description>A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments</description>
    <arm_group_label>NB-UVB+OTT</arm_group_label>
    <arm_group_label>Optimal topical therapy (OTT)</arm_group_label>
    <other_name>OTT</other_name>
    <other_name>Optimal local therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (≥18 years of age) patient meeting the UK working party criteria for atopic&#xD;
             eczema;&#xD;
&#xD;
          -  AE insufficiently controlled by standard topical care and therefore eligible for&#xD;
             NB-UVB or OTT;&#xD;
&#xD;
          -  Investigator Global Assessment (IGA, 0-4) of ≥ 2 (moderate disease);&#xD;
&#xD;
          -  Eczema Area and Severity Index (EASI) of ≥ 7 (moderate disease);&#xD;
&#xD;
          -  Understood and voluntarily signed and dated an informed consent form prior to any&#xD;
             study-related procedure or has a legal representative who has, and is willing to&#xD;
             comply with the study's requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication for NB-UVB;&#xD;
&#xD;
               -  Genetic defects associated with photosensitivity or skin cancer;&#xD;
&#xD;
               -  Heavily photo-damaged skin;&#xD;
&#xD;
               -  History of multiple (&gt;1) skin malignancies;&#xD;
&#xD;
               -  Use of systemic immunosuppressants/immunomodulators;&#xD;
&#xD;
               -  Use of medication associated with photosensitivity;&#xD;
&#xD;
          -  Patient is already on systemic AE therapy;&#xD;
&#xD;
          -  Patient is already on OTT in the past 2 months;&#xD;
&#xD;
          -  NB-UVB or any systemic therapy in the past 9 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise AA Gerbens, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam University Medical Centers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof. Phyllis I Spuls, MD PhD</last_name>
    <phone>+3120 566 9111</phone>
    <email>ph.i.spuls@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Knöps, MD</last_name>
    <phone>+3120 566 9111</phone>
    <email>e.knops@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert M Vodegel, MD PhD</last_name>
      <phone>+3158 286 6666</phone>
      <email>r.vodegel@mcl.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <state>Noord-Brabant</state>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique PM Andriessen, MD PhD</last_name>
      <phone>+3173 553 2000</phone>
      <email>m.andriessen@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Oosterwal</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <zip>1817 MS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Menno TW Gaastra, MD</last_name>
      <phone>+3172 515 7744</phone>
      <email>m.gaastra@centrum-oosterwal.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stef P Menting, MD PhD</last_name>
      <phone>+3120 510 8911</phone>
      <email>s.p.menting@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam Universitair Medische Centra</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Knöps, MD</last_name>
      <phone>+3120 566 9111</phone>
      <email>updatedermatologie@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huid Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 BJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise AA Gerbens, MD PhD</last_name>
      <phone>+3120 215 6060</phone>
      <email>L.Gerbens@huidmedischcentrum.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bergman Clinics</name>
      <address>
        <city>Haarlem</city>
        <state>Noord-Holland</state>
        <zip>2015 BJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lidian LA Lecluse, MD PhD</last_name>
      <phone>+3188 900 0500</phone>
      <email>l.lecluse@bergmanclinics.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Hoofddorp</city>
        <state>Noord-Holland</state>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert J Oosting, MD PhD</last_name>
      <phone>+3123 224 0000</phone>
      <email>aoosting@spaarnegasthuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijklander Ziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <state>Noord-Holland</state>
        <zip>1441 RN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick MJ Kemperman, MD</last_name>
      <phone>+31299 457 457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <zip>3813 TZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonie IM Majoie, MD</last_name>
      <phone>+3133 850 5050</phone>
      <email>iml.majoie@meandermc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <state>Zuid-Holland</state>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge M Haeck, MD PhD</last_name>
      <phone>+3115 260 3060</phone>
      <email>i.haeck@rdgg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Simone AE Stadhouders-Keet, MD</last_name>
      <phone>+3115 260 3060</phone>
      <email>s.stadhouders@rdgg.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deepak MW Balak, MD PhD</last_name>
      <phone>+3171 526 9111</phone>
      <email>d.m.w.balak@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Jan Hijnen, MD PhD</last_name>
      <phone>+3110 704 0704</phone>
      <email>d.hijnen@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>December 8, 2022</study_first_submitted>
  <study_first_submitted_qc>January 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>February 15, 2023</last_update_submitted>
  <last_update_submitted_qc>February 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Phyllis I. Spuls</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>atopic eczema</keyword>
  <keyword>atopic dermatitis</keyword>
  <keyword>NB-UVB</keyword>
  <keyword>phototherapy</keyword>
  <keyword>optimal topical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

